Table 2.
Baseline characteristics of patients with ankylosing spondylitis and rheumatoid arthritis
| AS (n = 15) | RA (n = 17) | p-value | |
|---|---|---|---|
| Age (years, mean ± SD) | 32.9 ± 9.6 | 56.2 ± 10.4 | <0.0001 |
| Sex (male, n (%)) | 12 (80.0 %) | 2 (11.8 %) | <0.0001 |
| ESR (mm/h, mean ± SD) | 53.7 ± 35.5 | 56.5 ± 31.3 | NS |
| CRP (mg/dL, mean ± SD) | 3.5 ± 3.5 | 2.9 ± 3.4 | NS |
| Disease duration (years, mean ± SD) | 5.2 ± 6.1 | 6.1 ± 6.3 | NS |
| Eye involvement (n (%)) | 5 (33.3 %) | N/A | |
| HLA-B27 positive (n (%)) | 13 (86.7 %) | N/A | |
| BASDAI (mean ± SD) | 4.3 ± 2.3 | N/A | |
| mSASSS (mean ± SD) | 15.8 ± 16.7 | N/A | |
| Sacroiliitis grading (n (%)) | |||
| Grade 2 | 3 (20.0 %) | N/A | |
| Grade 3 | 9 (60.0 %) | N/A | |
| Grade 4 | 3 (20.0 %) | N/A | |
| Current medications (n (%)) | |||
| MTX | 7 (46.7 %) | 14 (82.4 %) | 0.062 |
| SSZ | 8 (53.3 %) | 1 (5.9 %) | 0.005 |
| TNFi | 3 (20 %) | 1 (5.9 %) | 0.319 |
| NSAID | 13 (86.7 %) | 16 (94.1 %) | 0.589 |
AS ankylosing spondylitis, BASDAI bath ankylosing spondylitis disease activity index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, MTX methotrexate, N/A not available, NS not significant, NSAID nonsteroidal anti-inflammatory drug, RA rheumatoid arthritis, SSZ sulfasalazine, TNFi tumor necrosis factor inhibitor